Light activated technologies for oral cancer and wound treatments.
LightOx has developed a range of drug molecules for the treatment of Oral Cancer and the control of infection in wounds. Oral cancer clinical trials are scheduled for Q4 2024, and involve the topical addition of the lead candidate LXD191 to the cancerous lesion.
Read more